Recruiting

A Study of a Side Effects and Resource Navigation Program for People With Cancer

The purpose of this study is to find out if the navigation program helps participants manage immunotherapy treatment better than usual care. Investigators will also look at how the navigation program impacts participants' quality of life. Investigators will measure quality of life by having participants complete questionnaires.

ClinicalTrials.gov IDNCT07646847

PhaseNA

Enrollment200

SponsorMemorial Sloan Kettering Cancer Center

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Kidney Cancer, Bladder Cancer, Breast Cancer, Lung Cancer

About this study

Interventions

Other: Immunotherapy CARE Program — For participants assigned to the I CARE arm, CCNY staff will assist in monthly essential needs and side effects/symptom reporting navigation

Primary outcomes

Immune Checkpoint Inhibitors/ICI continuation (6 months)

Eligibility information

Inclusion Criteria: * Documentation of Disease o Patient must have pathologically confirmed kidney, bladder, breast, or lung cancer (per EMR) * Prior Treatment o Within three weeks (+/- 3 weeks) of starting PD-1 or PD(L)-1 immune checkpoint inhibitors as monotherapy or in combination with other therapies (per EMR) * Age ≥ 18 (per EMR) * Not Pregnant and Not Nursing (per self-report) * At least one essential need (e.g., food, transportation, housing), as determined by the ICCAN Essential Needs Screener (per self-report) * Lives in New York metro area, including Long Island, New Jersey, Connecticut, and Pennsylvania (per self-report) * Can speak English or Spanish (per self-report) * Has no significant psychiatric disturbance sufficient to preclude completion of the assessment measures, interview, or informed consent (i.e., acute psychiatric symptoms which require individual treatment) (per EMR, patient's care team, or study team) * Has no presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patient's care team, or study team)

Study locations

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York 10604 United States
City College of New York (Data Collection AND Specimen Analysis), New York, New York 10031 United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York 10065 United States
Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre, New York 11553 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.